For the Inventor, By the Inventor

Enter assignee name

Sarasota, FL, United States of America

Bridge Pharma Inc.

Calculating rank

USPTO Granted Patents = 34

% Expired Patents = 52.9

CIPO Patents = 3

EPO Patents = 7

Forward Citations = 263

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

A K Gunnar Aberg (23 out of 24 patents)

Vincent B Ciofalo (10 out of 10 patents)

Ak Gunnar Aberg (7 out of 8 patents)

4. Jan L Chen (7 out of 7 patents)

5. George Edward Wright (7 out of 21 patents)

6. Keith Johnson (4 out of 22 patents)

7. Andrew T Maioli (4 out of 4 patents)

8. Kresimir Pucaj (2 out of 2 patents)

9. Karl Reuter (2 out of 21 patents)

10. Viktor Meier (2 out of 8 patents)

11. Florian Stolz (2 out of 14 patents)

12. Eliso Gogritchiani (2 out of 2 patents)

13. Gunnar Aberg (2 out of 13 patents)

14. A K Aberg (2 out of 9 patents)

15. Paul J Fawcett (1 out of 1 patent)

Core Competencies:

Asthma Treatment

Ocular Formulations

Muscle Growth

Dermal Diseases

Pruritic Conditions

Non-Histaminergic Mechanisms

Neuropathic Pain

Urinary Incontinence

RR/SR-Ractopamine

Histamine H-4 Receptor

Smooth Muscle Spasmolytic Agents

Norketotifen

34 patents: Sort by Forward Citations

1. 11197851 - Methods of treatment of asthma and COPD (2021-12-14),

2. 10959992 - Methods of treatment of asthma and COPD (2021-03-30),

3. 9808419 - Medicinal treatment of dermal infectious disorders with norketotifen (2017-11-07),

4. 9694003 - Formulations and methods for treating high intraocular pressure (2017-07-04),

5. 9439895 - Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients (2016-09-13),

6. 9345697 - Methods of treatment of non-histaminic pruritus (2016-05-24),

7. 9333199 - Methods of treatment of histamine H-4 receptor-related pruritus associated with nerve disorders (2016-05-10),

8. 9138431 - Methods of treatment of histamine H-4 receptor-related pruritus (2015-09-22),

9. 8969385 - Ocular formulations of norketotifen (2015-03-03),

10. 8778971 - Medicinal treatment of dermal diseases in companion animals (2014-07-15),

11. 8765787 - Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen (2014-07-01),

12. 8741930 - Treating xerophthalmia with norketotifen (2014-06-03),

13. 8557846 - Medicinal treatment of dermal diseases in dogs (2013-10-15),

14. 8445542 - Methods of accelerating muscle growth, decreasing fat deposits and improving feed efficiency in livestock animals (2013-05-21),

15. 8383685 - Use of RR/SR-ractopamine (2013-02-26),

Company Overview

Bridge Pharma Inc. is a biotechnology company based in Sarasota, Florida, specializing in the development of innovative pharmaceutical solutions. The organization focuses on advancing drug delivery systems and enhancing therapeutic efficacy through cutting-edge research and technology. With a commitment to improving patient outcomes, Bridge Pharma engages in various research domains, including formulation science and pharmacokinetics, aiming to address unmet medical needs and contribute to the evolving landscape of healthcare.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

34 Patents

#9 in Sarasota, FL

#246 in Florida

#10,042 in US

#19,697 in the World

Sarasota, FL, United States of America

Bridge Pharma Inc.

Forward Citations = 263

15 inventors:

A K Gunnar Aberg (23 out of 24 patents)

Vincent B Ciofalo (10 out of 10 patents)

Ak Gunnar Aberg (7 out of 8 patents)

4. Jan L Chen (7 out of 7 patents)

5. George Edward Wright (7 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Bridge Pharma Inc.. Retrieved from https://idiyas.com/company/bridge-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…